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Rationale: Oral corticosteroids effectively treat asthma exacerbations but are associated with
well-described side effects.
Objective: This study compared the efficacy and safety of a high dose of an inhaled corticosteroid
with oral prednisolone in patients with worsening of their asthma after medication withdrawal.
Methods: Patients tapered off their inhaled corticosteroids until they reached predefined criteria
of ‘‘worsening asthma’’. Randomized patients (nZ 130) were treated double blind with either
ciclesonide 800 mg twice daily (starting with 800 mg hourly for 3 h after randomization) or prednis-
olone 40 mgoncedaily for 2weeks. Spirometry, daily asthma symptoms,morning andeveningpeak
expiratory flow and blood parameterswere assessed in all,methacholine challenge and inflamma-
tory measures were determined in induced sputum in a subset of patients.
Results: Ciclesonide was as effective as prednisolone in improving forced expiratory flow in 1 s,
morning peak expiratory flow and symptoms, the latter improving more rapidly with ciclesonide.
No differences were found in methacholine responsiveness or inflammatory measures in sputum
or blood. Ciclesonide caused significantly less reduction in morning plasma cortisol levels
(p< 0.0001).
Conclusion: This study shows that inhaled ciclesonide (800 mg twice daily) has comparable efficacy
tooralprednisolone (40 mgoncedaily) to regain asthmacontrol in patientswithasthmaworsening.
The more rapid onset and smaller effect on cortisol suppression suggest a better safety profile of
ciclesonide.
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Similar efficacy of ciclesonide versus prednisolone for treatment of asthma worsening after steroid tapering 1217Introduction (AM2þ, VIASYS Healthcare GmbH, Germany) for 7 days.Asthma exacerbations are common in patients with
moderately severe and severe asthma. They are a major
concern to the patient because of symptoms, forced
absence from work or school and interference with social
activities. They are also a burden to society due to the
inherent large economic costs, especially when associated
with hospitalisation.1
Currently, exacerbations are treated with an oral corti-
costeroid, at various doses and for various numbers of days.
This treatment is considered to be the ‘gold standard’ for
maximal anti-inflammatory and clinical efficacy, yet at the
price of potentially serious long-term and, occasionally,
very marked systemic side effects.2 Inhaled corticosteroids
exert their beneficial effects locally within the airways and
produce less systemic effects, although an effect on bone
marrow has been suggested.2 Few studies have directly
compared oral and inhaled corticosteroids as initial asthma
therapy or as treatment for asthma exacerbations.3e8
Results have generally shown similar effects on clinical and
inflammatory parameters, whereas daily treatment with
fluticasone 2000 mg was superior to prednisolone 30 mg for
14 days in improving methacholine responsiveness.7
Our hypothesis was that a high dose of inhaled cicleso-
nide would be as effective as oral prednisolone in treating
patients with asthma worsening after tapering off their
inhaled corticosteroids. Therefore we compared the effect
of both treatments, randomized and double blind, on peak
expiratory flow (PEF), symptom scores, lung function
including the concentration of methacholine causing the
forced expiratory volume in 1 s (FEV1) to drop by 20% (PC20
methacholine), and differential cell counts in blood and
induced sputum in patients who fulfilled predefined criteria
of asthma worsening after stepwise reduction of their
regular inhaled corticosteroid.
Patients and methods
Patients
The main inclusion criteria for this study were: age 18e75
years, a documented history of asthma, FEV1> 70% pre-
dicted and smoking history 10 pack years. Patients with
stable asthma were required to be on a constant dose of an
inhaled corticosteroid (beclomethasone 2000 mg/day or
equivalent) for at least 4 weeks prior to the first study visit.
Patients were not allowed to use the following medications
for at least 1 week prior to the first study visit: nedocromil,
theophylline, oral or inhaled long-acting beta-2 agonists,
lipoxygenase inhibitors or leukotriene antagonists, inhaled
anticholinergics or ketotifen, and inhaled disodium cro-
moglycate. Nasal and dermatologic steroids were allowed,
at constant dose during the study.
Study design
The study was performed as a randomized, double-blind,
double-dummy, parallel group study in six centers. During
the run-in period, all patients recorded their symptoms and
measured PEF twice daily using an electronic deviceThereafter, patients entered the first phase of the study, in
which they attended the outpatient clinic every 2 weeks for
up to 10 weeks. The individual dose of inhaled corticoste-
roids was reduced by 50% every second week. If the
randomization criteria were not met at a dose of beclo-
methasone 200 mg once daily or equivalent, inhaled corti-
costeroids were withdrawn completely. Throughout the
study, patients were allowed to use inhaled salbutamol
100 mg per puff as rescue medication. Patients were asked
to visit the research clinic earlier either when they had
symptoms of asthma worsening for which treatment was
felt necessary, or when their morning PEF had dropped by
more than 25% of their mean baseline PEF (defined as the
average value during the 7 days of the run-in period).
Patients were considered to have worsening of their
asthma if they fulfilled all three following randomization
criteria: (1) a reduction of more than 25% of either baseline
FEV1 (i.e. measured at the start of the run-in period) or
a reduction in morning PEF by at least 25% on two consec-
utive days immediately prior to a visit (compared to the
average value during the 7 days of the run-in period); and
(2) either an increase in symptoms (wheezing and/or
shortness of breath) despite repeated daily use of rescue
medication or an increase of at least four puffs daily in
baseline rescue medication on two consecutive days
immediately prior to a visit; and 3) either reversibility of
FEV1 of at least 15% from baseline FEV1 after inhaled sal-
butamol 400e800 mg or a diurnal PEF fluctuation of at least
15% for 3 or more of the last 7 days of run-in (diurnal PEF
fluctuation is calculated by the following formula: ([higher
PEF lower PEF] 100)/(0.5 [higher PEFþ lower PEF).
Once patients suffered from asthma worsening according to
these criteria, they were randomized to either inhaled
ciclesonide or oral prednisolone 40 mg daily for 2 weeks.9
The starting dose of ciclesonide was 800 mg via metered-
dose inhaler (4 200 mg metered dose) every hour for the
first 3 h with an additional dose in the evening on the first
day, and 800 mg twice daily thereafter. Randomization was
performed with stratification according to FEV1, current
smoking status and dose of inhaled corticosteroid at the
time of inclusion. During treatment, all patients recorded
home PEF measurements twice daily, and scored daytime
and nighttime asthma symptoms (each scale ranging from
0 [no symptoms] to 4 [severe symptoms]) and daily use of
rescue medication. Before and after treatment, lung
function was measured and blood collected for differential
cell counts and serum cortisol, which was measured using
high performance liquid chromatography with tandem mass
spectroscopy. Serum cortisol was measured at the time of
asthma worsening and after treatment at the same time of
the day (eight o’clock in the morning 0.5 h). In addition,
methacholine challenge and sputum induction were per-
formed before and after treatment in selected centers. At
each visit the occurrence of adverse events was checked by
a research physician. For safety reasons, patients were
given an emergency contact telephone number to be able
to contact a research physician out of normal working
hours. Written informed consent was obtained from
patients before the start of the study and the study
protocol was approved by the local medical ethical
committee of each participating centre.
Number of patients enrolled
n=229
Not randomized, n=99
(patients did not meet the predefined criteria of asthma worsening)
Randomized to receive inhaled ciclesonide
n=67
Randomized to receive oral prednisolone
n=63
Withdrawn from the study, n=2
(due to perceived lack of efficacy)
Withdrawn from the study, n=1
(due to perceived lack of efficacy)
Completed the trial, n=65 Completed the trial, n=62
Figure 1 Flow diagram of patients enrolled, randomized and completing the study.
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FEV1, forced vital capacity (FVC), and mean forced
expiratory flow between 25% and 75% of vital capacity
(FEF25e75%) were measured with a calibrated spirometer
according to standardized guidelines as described previ-
ously.7 Patients measured their PEF using an electronic
device (AM2þ, VIASYS Healthcare GmbH, Germany). The
best of three measurements was used for analysis. Patients
were carefully instructed to measure their PEF in the
morning before the use of any medication and in the
evening, if possible, after withholding their rescue medi-
cation for at least four hours. Methacholine challenges
were performed with a dosimeter method.10 Methacholine
was prepared in 0.9% saline to produce concentrations
ranging from 0.038 to 8 mg/ml.
Sputum induction and sputum processing
Sputum was induced by inhalation of hypertonic saline
aerosols as previously described.7 Fifteen minutes after
salbutamol (200 mg) inhalation, hypertonic saline (3%, 4%,
and 5%) was nebulized at each concentration over 7 min.
Sputum ‘plugs’ were processed according to the method of
Hargreave et al. with some modifications.11 The concen-
tration of eosinophilic cationic protein (ECP) in sputum was
measured using a fluoroenzymatic assay, the ImmunoCAP
ECP (provided by Pharmacia, Uppsala, Sweden).
Statistical methods
A non-inferiority analysis was performed for the primary
variable, morning PEF in the per-protocol analysis (defined
as the absence of any major protocol violations including
the violation of entry criteria). The primary hypothesis was
non-inferiority of ciclesonide 800 mg twice daily compared
to prednisolone 40 mg once daily with regard to the primary
variable; the acceptance limit for non-inferiority was
25 l/min based on the lower limit of the 95%-confidenceintervals for the between-treatment differences. A power
calculation was performed assuming: aZ 0.025 (one-
sided), non-inferiority acceptance limitZ25 l/min with
a common standard deviationZ 45 l/min. Assuming that
approximately 80% of all randomized patients were
included in the per-protocol analysis, 60 patients per group
needed to be randomized to obtain 50 evaluable patients
per group. Finally, analyses of morning PEF were performed
using analysis of covariance (ANCOVA) with treatment, sex,
and center pool, as well as the stratification factors FEV1,
smoking habit and inhaled corticosteroid dose pre-treat-
ment as fixed factors and age as covariate. Between-
treatment differences of asthma symptoms, use of rescue
medication, sputum and blood parameters were analyzed
non-parametrically by means of the ManneWhitney U test.
Results
A total of 229 patients were enrolled in the study. Of these
229 patients, 99 were not randomized because they did not
achieve the predefined criteria of asthma worsening during
or at the end of the 10-week steroid-tapering period. A
total of 127 out of 130 randomized patients completed
phase 2 of the study (Fig. 1). The baseline characteristics at
the start of the study are presented in Table 1 and did not
differ between ciclesonide (nZ 67) and prednisolone
(nZ 63) groups. Methacholine responsiveness and sputum
induction were measured and performed in a subset of
patients: PC20 methacholine was determined in 81 patients
(42 in the ciclesonide group and 39 in the prednisolone
group). Sputum induction was performed in 55 patients (29
in the ciclesonide group and 26 in the prednisolone group).
Peak expiratory flow, other lung function,
and symptoms
Mean morning PEF was significantly higher after two weeks
of treatment following asthma worsening in both groups
(Table 2, Fig. 2). Non-inferiority of ciclesonide compared to
Table 1 Baseline characteristics of the study population.a
Ciclesonide
at time of
enrollment
(nZ 67)
Ciclesonide at time of
asthma worsening
(nZ 67)
Prednisolone
at time of
enrollment
(nZ 63)
Prednisolone
at time of
asthma worsening
(nZ 63)
Age, yrsa,b 45 13.3 45 12.9
Gender, male/female 40/27 33/30
Smoking, n (%)
Current 26 (39%) 25 (40%)
Use of ICS at time of asthma worsening
No ICS, n (%) 0 (0) 35 (52%) 0 (0) 31 (49%)
ICS, n (%) 67 (100) 32 (48%) 63 (100) 32 (51%)
Dose of ICS, mg/dayb 1000 (1000e2000) 200 (0e1000) 1000 (800e2000) 200 (0e1000)
FEV1, %predicted 89.6 15.2 71.3 16.6 88.5 14.3 69.8 15.9
FEV1, l 2.85 0.75 2.27 0.73 2.89 0.85 2.28 0.78
Reversibility, % initial 24.1 10.0 25.5 11.3
AM PEF, l 384.9 112.0 284.6 92.5 402.8 114.3 291.1 86.7
PM PEF, l 409.6 113.6 352.7 103.8 418.2 117.9 354.1 118
Diurnal PEF fluctuation, % 11.4 7.8 15.1 7.5 9.0 4.8 13.8 6.8
PC20 methacholine, mg/ml
d,c 1.94 (0.06e16.0) 0.59 (0.03e16.0) 1.16 (0.02e16.0) 0.56 (0.04e16.0)
Total daily
symptom scoreb
1.0 (0.0e1.0) 4.0 (2.0e5.0) 1.0 (0.0e2.0) 4.0 (2.0e5.0)
Number daily
puffs rescue medication
1.0 (0.0e2.0) 4.4 (2.4e7.6) 1.0 (0.0e2.0) 3.7 (2.0e6.6)
Blood eosinophils, %b 3.0 (2.0e5.0) 5.0 (3.0e9.0) 4.0 (2.0e6.0) 5.0 (4.0e7.0)
Serum cortisol, nmol/liter 382 130 371 166
Sputum ECP, mg/mld,b 55.2 (18.7e88.5) 37.3 (6.9e172.0)
Sputum eosinophils, %d,b 0.9 (0.3e16.8) 2.4 (0.4e7.9)
Sputum neutrophils, %d,b 31.2 (14.5e43.8) 38.4 (17.5e59.3)
Sputum macrophages, %d,b 44.0 (34.4e70.2) 41.7 (23.6e63.2)
Sputum lymphocytes, %d 0.3 (0.1e0.7) 0.2 (0.0e0.6)
Sputum bronchial
epithelial cells, %d,b
3.6 (1.6e10.1) 3.4 (1.0e7.2)
a Values are expressed as mean standard deviation, unless specified otherwise.
b Median (interquartile range), dose equivalent to beclomethasone.
c Geometric mean (range).
d A methacholine challenge was performed in 42 patients in the ciclesonide groups and in 39 patients of the prednisolone group,
a sputum induction was performed in 29 and 26 patients respectively, and sputum ECP was measured in 17 and 18 patients using
ciclesonide and prednisolone respectively.
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as the lower limit of the 95%-confidence interval of the
treatment difference in PEF (20.7 l/min) did not exceed
the pre-specified non-inferiority acceptance limit of 25 l/
min. The intention to treat analysis similarly showed non-
inferiority of ciclesonide with the lower limit of the 95%-
confidence interval of the treatment difference in PEF being
15.5 l/min. We also analyzed subgroups of patients with
either a more severe drop in their FEV1 or PEF on the one
hand and patients with a higher percentage of sputum
eosinophils at the start of treatment on the other hand.
These subgroup analyses showed similar results. Firstly, we
analyzed a subgroup of patients with a drop in either FEV1
or PEF of more than 30%. The mean improvement in morning
PEF was 49.8 l/min for ciclesonide [nZ 32] and 49.4 l/min
for prednisolone [nZ 28], pZ 0.97. Secondly, we analyzed
a subgroup of patients with a high percentage (>3%)
of sputum eosinophils. Mean improvement in morning PEF
was 80.5 l/min for ciclesonide [nZ 13] and 76.1 l/minfor prednisolone [nZ 13] in patients with >3% sputum
eosinophils.
No significant differences were found for change in
evening PEF, FEV1, FVC, and FEF25e75% (Table 2). In addi-
tion, reduction in diurnal PEF fluctuation was significantly
more pronounced after treatment with ciclesonide than
after prednisolone (mean values being 3.0% and 0.6%
respectively, pZ 0.03). Furthermore, PC20 methacholine
improved to a similar extent after 2 weeks of treatment
with ciclesonide and prednisolone (mean improvement: 1.3
and 0.9 doubling concentrations respectively, pZ 0.15).
There was no difference in total symptom scores between
the groups after 2 weeks of treatment. However, during
the first three treatment days, total symptom scores
improved to a greater extent after treatment with cicle-
sonide than with prednisolone. By the second treatment
day, the improvement in total symptom score was signifi-
cantly greater for ciclesonide than for prednisolone
(median: 1.0 versus 0.5 respectively, pZ 0.02) (Fig. 3).
Table 2 Changes in clinical and inflammatory measurements after 2 weeks treatment.a
Change in Ciclesonide Prednisolone p-Value
Morning PEF, l/min 51.6 7.2 54.2 6.9 0.92
Evening PEF, l/min 41.7 6.5 55.8 6.5 0.12
FEV1, l 0.44 0.05 0.39 0.05 0.42
FVC, l 0.51 0.06 0.50 0.06 0.87
FEF25e75, l 0.48 0.09 0.34 0.09 0.24
PC20 Methacholine, DC
c 1.28 0.22 0.86 0.23 0.17
Diurnal PEF fluctuation, %d 3.0 1.1 0.6 1.1 0.03
Total symptom score 1.6 (2.3 to 0.6) 1.2 (2.3 to 0.2) 0.24
Number of puffs
rescue medication/day
2.4 2.8 1.7 3.0 0.15
Percentage of days
without nocturnal awakenings
82.5 27.1 79.0 28.3 0.29
Blood
Eosinophils, % 1.0 (3.0 to 0.5) 4.0 (7.0 to 3.0) <0.001
Neutrophils, % 1.5 (2.5 to 5.5) 15.0 (4.0e22.0) <0.001
Lymphocytes, % 0.0 (3.0 to 4.0) 5.0 (14.0 to 3.0) <0.001
Monocytes, % 0.0 (1.0 to 1.0) 2.0 (4.0 to 0.0) <0.001
Basophils, % 0.0 (1.0 to 0.0) 1.0 (1.0 to 0.0) 0.03
Sputum
Eosinophils, %b 0.3 (11.6 to 0.1) 1.35 (7.8 to 0.3) 0.54
Lymphocytes, %b 0.0 (0.5 to 0.3) 0.0 (0.5 to 0.2) 0.69
Macrophages, %b 7.5 (8.6 to 27.1) 2.6 (10.2 to 21.5) 0.85
Neutrophils, %b 2.8 (13.8 to 11.2) 5.2 (24.7 to 12.2) 0.69
Bronchial epithelial cells, %b 1.8 (2.0 to 3.3) 1.7 (0.6 to 11.4) 0.40
ECP, ng/mlb 43.2 (82.5 to 2.7) 16.1 (109.2 to 3.3) 0.99
Serum cortisol, nmol/lb 67.3 13.1 338.5 13.2 <0.0001
a Values are expressed as mean standard error of the mean unless specified otherwise.
b Median with interquartile range.
c Doubling concentration.
d Daily diurnal PEF fluctuation is calculated by the following formula: ((higher PEF lower PEF) 100)/(0.5 (higher PEFþ lower
PEF)).
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symptom scores during the first week, a significant differ-
ence was still found between the two treatments in favour
of ciclesonide (pZ 0.03) (Fig. 3). No significant differences
between the groups were found for use of rescue medica-
tion or percentage of days without nocturnal awakenings.
Overall, two patients in the ciclesonide group and one
patient on prednisolone were withdrawn from the study
because of perceived lack of efficacy.
Sputum and blood cell differential counts and
eosinophilic cationic protein
The percentage of eosinophils and the ECP concentration in
induced sputum decreased significantly with both treat-
ment groups (Table 2, Fig. 4). No differences in sputum cell
differential counts and ECP levels were found. The
percentage of blood eosinophils, basophils, lymphocytes,
and monocytes decreased significantly more with oral
prednisolone than inhaled ciclesonide, whereas the
percentage of neutrophils increased significantly more with
prednisolone treatment.Potential adverse effects
Morning serum cortisol levels were significantly more
reduced with oral prednisolone (mean reduction in serum
cortisol: 67.3 nmol/l for ciclesonide and 338.5 nmol/l
for prednisolone; p< 0.0001) (Fig. 5). No serious adverse
events were reported. In total, 48 patients experienced 86
adverse events during phase two of this study. Thirty-nine
adverse events were reported in 26 out of 67 patients
receiving ciclesonide, whereas 47 adverse events were
reported in 22 out of 63 patients taking oral prednisolone.
Table 3 shows the most frequently occurring adverse
events, i.e. adverse events occurring in at least three
patients in at least one treatment group.
Discussion
This study shows that 2 weeks of treatment with a high dose
of inhaled ciclesonide is as effective as a course of oral
prednisolone in patients with worsening asthma after
tapering off their inhaled corticosteroids. No difference in
the primary endpoint, morning PEF, was found between
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Figure 2 Improvement in morning and evening PEF during treatment with ciclesonide and prednisolone. Data are presented as
mean with standard error of the mean.
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Figure 3 Improvement in total daily symptom scores during
treatment with ciclesonide and prednisolone. Data are pre-
sented as median with 95%-confidence interval. At day 1, there
is a trend for a difference between ciclesonide and predniso-
lone (pZ 0.07). At day 2, there is a significant difference
between ciclesonide and prednisolone (pZ 0.03). When the
values during the first 7 days of treatment are added up, there
is a significant difference between ciclesonide and predniso-
lone (pZ 0.03).
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variability was significantly more reduced and symptoms
improved significantly faster with ciclesonide. In addition,
improvement in FEV1, PC20 methacholine, and airway
inflammation as reflected by the percentage of sputum
eosinophils, was very similar in the two treatment groups.
Ciclesonide caused significantly less suppression of morning
plasma cortisol than oral prednisolone.
A previous study by Meijer and colleagues showed that
a high dose of inhaled fluticasone (2000 mg daily) was as
effective as oral prednisolone 30 mg in improving lung
function and airway inflammation in 120 asthmatic patients
who tapered off their inhaled corticosteroids.7 Although
some of the patients in this study experienced an increase
in symptoms requiring oral prednisolone, others remained
clinically stable even after they had discontinued their
inhaled corticosteroids completely for 3 weeks. We have
confirmed the findings of Meijer and colleagues, now using
ciclesonide. Our patients had to meet strict predefined
criteria of worsening of their asthma including a fall of at
least 25% of baseline FEV1 or mean morning PEF in addition
to meeting criteria of increased symptoms and reversibility
of airway obstruction. In our study, most patients suffered
from a relatively mild asthma exacerbation. It is unclear,
whether our results can be extrapolated to patients with
more severe exacerbation, since a more severe peripheral
airway obstruction might hamper aerosol delivery to the
lung periphery producing less benefit of inhaled as opposed
to oral corticosteroids.12,13 To further explore this issue, we
have also analyzed patients with either a drop in FEV1 or
PEF of more than 30% from baseline or a percentage of
sputum eosinophils higher than 3%. Results were similar in
these patients, i.e. comparable efficacy of ciclesonide and
prednisolone.
In the present study, asthma worsening was induced by
gradual reduction of inhaled corticosteroids, a model intro-
duced byGibson and colleagues.14 Although poor compliance
with maintenance treatment with inhaled corticosteroids
can lead to asthma worsening, other common triggers
include viruses and exposure to aero-allergens. Several
authors have shown that asthma worsening after steroid
reduction is predominantly characterised by a higher
percentage of eosinophils in sputum and blood, whereas
spontaneous exacerbations are predominantly characterisedby higher percentages of sputum neutrophils.14e17 Clearly
eosinophils are particularly sensitive to corticosteroids,
which might cast doubt on whether our findings can be
extrapolated to spontaneous exacerbations. This is,
however, likely, since Di Franco and coworkers recently
demonstrated that a high dose of inhaled fluticasone
(2000 mg daily) was as effective as a course of oral prednis-
olone in improving sputum eosinophilia and airway obstruc-
tion in patients with a spontaneous asthma exacerbation.18
However, oral prednisolone was gradually reduced reaching
a final dose of 10 mg daily at the time the comparison was
made with inhaled fluticasone. Since 2000 mg of inhaled flu-
ticasone corresponds to 17 mgoral prednisolonewith respect
to cortisol suppression, at least part of the efficacy of this
high a dose of fluticasone may be attributed to systemic
Table 3 Most frequently occurring adverse events (i.e. in
at least three patients) during treatment.a
Ciclesonide
nZ 67
Prednisolone
nZ 63
Blood leukocytosis 0 (0) 10 (16)
Palpitations 1 (2) 3 (5)
Headache 3 (5) 3 (5)
Asthma aggravated 3 (5) 2 (3)
Dyspnea not otherwise specified 3 (5) 0 (0)
Nasopharyngitis 1 (2) 3 (5)
a Data expressed as numbers with percentage in parentheses.
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Figure 4 Individual changes in % of sputum eosinophils with
treatment of ciclesonide or prednisolone.
1222 M. van den Berge et al.effects of the drug.19,20 Thus, we have extended the findings
of Di Franco and colleagues in several ways. Firstly, we have
compared a high dose of inhaled ciclesonide with a contin-
uous high dose of oral prednisolone (40 mg daily) over two
weeks. In thisway,wewere able to corroborate their findings
with regard to improvement in sputum eosinophilia.
Secondly, we have also clearly demonstrated in a non-infe-
riority analysis that inhaled ciclesonide is as effective as oral
prednisolone in improving morning PEF. Furthermore, we
have demonstrated a similar efficacy with regard to
improvement in FEV1 and methacholine responsiveness and,
importantly, the effect of ciclesonide on diurnal PEF fluctu-
ation was significantly greater and significantly faster in
producing symptom improvement than prednisolone.
The present study used the novel inhaled corticosteroid
ciclesonide. This is a topically active inhaled corticosteroid
that is converted in situ by airway esterase activity in the
lung to its active metabolite desisobutyryl ciclesonide.21
Desisobutyryl ciclesonide is 99% plasma-protein bound
resulting in a very low free unbound circulating concen-
tration.22 In a recent study by Lee and colleagues, it was
demonstrated that inhaled ciclesonide 1600 mg daily was as
effective as fluticasone 2000 mg daily in improving airway
methacholine responsiveness and exhaled nitric oxide, but
without an effect of ciclesonide on the hypothalamice
pituitaryeadrenal (HPA) axis.13 In agreement with this,
Szefler and colleagues could not identify any effect on the
HPA axis (as measured by 24-hour cortisol measurements)
even at high doses of inhaled ciclesonide up to 1600 mg.23 In0
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Figure 5 Change in morning serum cortisol during treatment
with ciclesonide and prednisolone. Data are presented as mean
with standard error of the mean.contrast to these studies, we found a small but statistically
significant reduction in morning serum cortisol levels. This
discrepancy may well be explained by a lack of power of
the former studies, since they were relatively small with
a maximum of 14 included subjects per treatment arm.
Notwithstanding the statistically significant reduction in
cortisol, the extent of this was very small (i.e. a decrease of
18% from baseline) and of no clinical relevance, indicating
a good safety profile of even high-dose inhaled ciclesonide
compared to a standard dose of oral prednisolone which
produced the expected marked effect on the HPA axis (i.e.
a decrease of 90% from baseline). This opens avenues for
further study to assess whether patients using ciclesonide
can simply increase the dose in the case of a pending
asthma exacerbation. In addition, there were no serious
adverse events for either treatment. Finally, no cases of
oral candidiasis or hoarseness were reported in this study.
Thus, our study confirms previous findings of negligible local
adverse effects with ciclesonide even when high doses are
used.24,25 Taken together, ciclesonide appears to be
a potent inhaled corticosteroid with a favourable systemic
safety profile compared with oral prednisolone.
Finally, we found a significantly greater improvement in
total symptom scores during the first treatment days,
although this difference disappeared after the first week of
treatment. In agreement with this, Belda and colleagues
recently showed that a high dose fluticasone (4000 mg) more
rapidly reduces airway inflammation (as reflected by the
percentage of sputum eosinophils) in patients with an acute
asthma exacerbation than oral prednisolone (30 mg).26 In
their study, inhaled fluticasone decreased the percentage
of sputum eosinophils as early as 2 h after inhalation,
reaching a maximum at 6 h after inhalation. Prednisolone
also reduced sputum eosinophilia, but with effects being
noticeable only at 6 h after administration and the effects
were weaker than those of fluticasone. Twenty-four hours
after treatment, there was still a slightly greater reduction
in sputum eosinophilia after treatment with fluticasone,
but the difference with prednisolone treatment was much
smaller. Taken together, these findings suggest that inhaled
corticosteroids have a more rapid onset of action than oral
prednisolone which could be explained by its local effects
in the central and peripheral airways. For this reason, it is
tempting to speculate that we would have found significant
differences in airway hyperresponsiveness and sputum
eosinophilia between inhaled ciclesonide and oral pred-
nisolone if a PC20 methacholine and sputum induction had
been performed earlier after the start of treatment.
Similar efficacy of ciclesonide versus prednisolone for treatment of asthma worsening after steroid tapering 1223In conclusion, the results of our study suggest that a high
dose of inhaled ciclesonide is at least as effective as oral
prednisolone in patients with asthma worsening after
withdrawal of inhaled corticosteroids. Ciclesonide produces
more rapid improvement of symptoms and has the advan-
tage of less pronounced reduction in serum cortisol
concentrations and similar adverse effects.
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